Clinical trials: HER2 + Gastric Cancer
Breast Cancer, Gastric Cancer
IKS014 in Advanced Solid Tumors That Express HER2
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT05872295
- Testing
- IKS014
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 165 people
- Sponsor
- Iksuda Therapeutics Ltd.
HER2 Expressing Solid Tumors
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
- Trial name
- SENTRY-HER2 (NCT07192432)
- Testing
- Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT07431281
- Testing
- Sonesitatug vedotin, Rilvegostomig, Nivolumab
- Where
- 314 sites in United States, Australia and 22 more
- Volunteers
- 2,130 people
- Sponsor
- AstraZeneca
HER 2 Positive Advanced Gastric Cancer
A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
To explore overall response rate of trastuzumab combined with TS-ONE based chemotherapy in first-line HER2-positive advanced gastric cancer.
- Trial name
- NCT01736410
- Testing
- Trastuzumab, TS ONE, Cisplatin
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies.
- Trial name
- NCT02264678
- Testing
- Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
- Trial name
- NCT06560528
- Testing
- combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Gastric Carcinoma, HER2-positive Gastric Cancer
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.
- Trial name
- NCT05313906
- Testing
- RC48+AK105+cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of…
- Trial name
- NCT01260194
- Testing
- trastuzumab [Herceptin]
- Where
- 6 sites in India
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Head and Neck Cancer, Liver Cancer
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors.
- Conditions
- Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT01171924
- Testing
- CUDC-101
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Curis, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin hydrochloride, cisplatin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT01123473
- Testing
- capecitabine, cisplatin, epirubicin hydrochloride
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 29 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HER2-positive Gastric Cancer, Immunotherapy
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
At present, there is no anti-HER2 therapy recommended by guidelines for second-line treatment of advanced gastric cancer with HER2-positive or HER2-overexpression, and combined with anti-angiogenic drugs are mainly used.
- Trial name
- NCT05982834
- Testing
- Disitamab Vedotin combined with fruquintinib and Tislelizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
HER2-positive Gastric Cancer
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
- Trial name
- NCT06439550
- Testing
- Serplulimab, Trastuzumab, Oxaliplatin + Tegafur
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced HER2-positive Breast Cancer or Gastric Cancer
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
This is a multicenter, open-label, dose escalation, phase I study to estimate the Maximum Tolerated Dose (MTD) or a lower Recommended Dose for Expansion (RDE) of LJM716 in combination with trastuzumab in patients with Human…
- Trial name
- NCT01602406
- Testing
- LJM716, Trastuzumab
- Where
- 11 sites in United States, Belgium and 7 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive…
- Trial name
- NCT03615326
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 192 sites in United States, Australia and 18 more
- Volunteers
- 738 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach
The purpose of this study is to determine the rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference…
- Trial name
- HerFLOT (NCT01472029)
- Testing
- 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Cancer
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
This prospective, multi-center, non-interventional study will evaluate the efficacy and safety of trastuzumab in routine clinical practice in Chinese participants with gastric or gastro-oesophageal cancer.
- Trial name
- EVIDENCE (NCT01839500)
- Testing
- Trastuzumab
- Where
- 81 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
This Phase 1b trial is an open label, multi-center study of XMT-1522 administered as an intravenous infusion once every three weeks.
- Conditions
- Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer
- Trial name
- NCT02952729
- Testing
- XMT-1522
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Mersana Therapeutics
HER2-positive Gastric Cancer
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease…
- Trial name
- NCT05070598
- Testing
- Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shengjing Hospital